The Significance of Remdesivir and Favipiravir Therapies to Survival of COVID-19 Patients
Maysaa K. Al-Malkey*
, Sinai W. Mohammed , Noorulhuda F Khalaf , Mohammed J. Al-Obaidi and Fadhaa O. Sameer Tropical Biological Research Unit, College of Science, University of Baghdad, Baghdad, Iraq
Corresponding Author E-mail:maysakadhim@uobaghdad.edu.iq
Abstract: The coronavirus disease 2019 (COVID-19) pandemic and the infection escalation around the globe encourage the implementation of the global protocol for standard care patients aiming to cease the infection spread. Evaluating the potency of these therapy courses has drawn particular attention in health practice. This observational study aimed to assess the efficacy of Remdesivir and Favipiravir drugs compared to the standard care patients in COVID-19 confirmed patients. One hundred twenty-seven patients showed the disease at different stages, and one hundred and fifty patients received only standard care as a control group were included in this study. Patients under the Remdesivir therapy protocol were (62.20%); meanwhile, there (30.71%) were under Favipiravir therapy. From the total number of patients under both protocols, 75.6% of the total patients recovered, and 15.7% were deceased. The mortality rate was shown to be 14 out of 64 patients (22%) in critical COVID-19 patients in the Remdesivir group and 3 out of 37 patients (8%) in the Favipiravir group. Remdesivir drug lowered healing mean time to 6 days in mild-to-moderate. COVID-19 clinical manifestations are different among infected patients, and the therapy required to be carefully designed for critical cases in particular. Remdesivir and Favipiravir therapy tend to have a promising efficacy in reducing the mortality rate and time of recovery, especially among mild-to-moderate patients.
Keywords: COVID-19; Favipiravir; Remdesivir; Survival Back to TOC